Skip to Main Content

Paper Details

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.
Elife
33
2021
N, S1 receptor, S2 subunit, SARS, SARS-CoV, SARS-CoV-2, SARS-CoV-2 spike
Animals, Antibodies, Neutralizing, Antibodies, Viral, Binding Sites, COVID-19, Camelids, New World, Epitopes, HEK293 Cells, Humans, Male, Neutralization Tests, SARS-CoV-2, Single-Domain Antibodies, Spike Glycoprotein, Coronavirus
Author NameAffiliation
Fred D MastCenter for Global Infectious Disease Research, Seattle Children's Research Institute
Peter C FridyThe Rockefeller University
Natalia E KetarenThe Rockefeller University
Junjie WangThe Rockefeller University
Erica Y JacobsThe Rockefeller University
Erica Y JacobsSt. John's University
Paul OlivierCenter for Global Infectious Disease Research, Seattle Children's Research Institute
Tanmoy SanyalDepartment of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California san francisco
Kelly R MolloyThe Rockefeller University
Kelly R MolloyThe Rockefeller University
Fabian SchmidtThe Rockefeller University
Magdalena RutkowskaThe Rockefeller University
Yiska WeisblumThe Rockefeller University
Lucille M RichCenter for Immunity and Immunotherapies, Seattle Children's Research Institute
Elizabeth R VanderwallCenter for Immunity and Immunotherapies, Seattle Children's Research Institute
Nicholas DambrauskasCenter for Global Infectious Disease Research, Seattle Children's Research Institute
Vladimir VigdorovichCenter for Global Infectious Disease Research, Seattle Children's Research Institute
Sarah KeeganNYU Grossman School of Medicine
Sarah KeeganNYU Grossman School of Medicine
Jacob B JilerThe Rockefeller University
Milana E SteinThe Rockefeller University
Paul Dominic B OlinaresThe Rockefeller University
Louis Herlands
Theodora HatziioannouThe Rockefeller University
David Noah SatherCenter for Global Infectious Disease Research, Seattle Children's Research Institute
David Noah SatherUniversity of Washington
Jason S DebleyCenter for Immunity and Immunotherapies, Seattle Children's Research Institute
Jason S DebleyUniversity of Washington
Jason S DebleySeattle Children's Hospital
David Feny??NYU Grossman School of Medicine
David Feny??NYU Grossman School of Medicine
Andrej Sali (CM4AI)Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California san francisco
Andrej Sali (CM4AI)Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California san francisco
Paul D BieniaszThe Rockefeller University
Paul D BieniaszHoward Hughes Medical Institute, The Rockefeller University
John D AitchisonCenter for Global Infectious Disease Research, Seattle Children's Research Institute
John D AitchisonUniversity of Washington
John D AitchisonUniversity of Washington
Brian T ChaitThe Rockefeller University
Brian T ChaitThe Rockefeller University
Michael P RoutThe Rockefeller University
Michael P RoutThe Rockefeller University
  • 1 - 42

Datasets